These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38293566)

  • 21. A disproportionality analysis of adverse events associated to pertuzumab in the FDA Adverse Event Reporting System (FAERS).
    Zou SP; Yang HY; Ouyang ML; Cheng Q; Shi X; Sun MH
    BMC Pharmacol Toxicol; 2023 Nov; 24(1):62. PubMed ID: 37957717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database.
    Rong L; Xie M; Jiang M; Qiu H; Kong L
    Br J Clin Pharmacol; 2024 Aug; 90(8):1816-1826. PubMed ID: 36702463
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A real-world disproportionality analysis of cyclosporine from the FDA Adverse Event Reporting System (FAERS) database.
    Cui S; Li L; Liu W; Zhao B; Zhong X
    Braz J Med Biol Res; 2024; 57():e13392. PubMed ID: 39082578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vonoprazan-associated
    Ouyang M; Zou S; Cheng Q; Shi X; Zhao Y; Sun M
    Ther Adv Drug Saf; 2024; 15():20420986241260211. PubMed ID: 39091466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib.
    Yin Y; Shu Y; Zhu J; Li F; Li J
    Sci Rep; 2022 Nov; 12(1):19555. PubMed ID: 36380085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A real-world pharmacovigilance analysis of the FDA adverse event reporting system events for polatuzumab vedotin.
    Xu Z; Huang D; Liu Q; Liu S; Liu J; Wang H; Shen Z
    Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38695550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Hyponatraemia and Antidepressant Drugs: A Pharmacovigilance-Pharmacodynamic Assessment Through an Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
    Mazhar F; Pozzi M; Gentili M; Scatigna M; Clementi E; Radice S; Carnovale C
    CNS Drugs; 2019 Jun; 33(6):581-592. PubMed ID: 30977109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
    Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
    Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
    [No Abstract]   [Full Text] [Related]  

  • 29. Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023.
    Yang Y; Wei S; Tian H; Cheng J; Zhong Y; Zhong X; Huang D; Jiang C; Ke X
    Front Pharmacol; 2024; 15():1439115. PubMed ID: 39101151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
    Cui Z; Cheng F; Wang L; Zou F; Pan R; Tian Y; Zhang X; She J; Zhang Y; Yang X
    Front Pharmacol; 2023; 14():1259908. PubMed ID: 37954852
    [No Abstract]   [Full Text] [Related]  

  • 31. Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study.
    Liu F; Yin G; Xue S; Rehman FU; Liao D; Pan Y
    J Cancer; 2023; 14(17):3275-3284. PubMed ID: 37928419
    [No Abstract]   [Full Text] [Related]  

  • 32. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
    Rana P; Aleo MD; Wen X; Kogut S
    Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database.
    Liu Y; Li H; Hu C; Tan L; Yin P; Li Z; Zhou S; Su L
    Front Pharmacol; 2024; 15():1368244. PubMed ID: 38873427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced QT prolongation and torsade de pointes: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database.
    Li D; Chai S; Wang H; Dong J; Qin C; Du D; Wang Y; Du Q; Liu S
    Front Pharmacol; 2023; 14():1259611. PubMed ID: 38186652
    [No Abstract]   [Full Text] [Related]  

  • 37. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
    Yang Q; Wang J; Wang M; Zhang S; He QQ
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system.
    Wei W; Chen L; Zhou H; Liu J; Zhang Y; Feng S; Bai Y; Leng Y; Chang E; Huang L
    Front Pharmacol; 2023; 14():1208456. PubMed ID: 37645441
    [No Abstract]   [Full Text] [Related]  

  • 39. Post-marketing drug safety surveillance of enfortumab vedotin: an observational pharmacovigilance study based on a real-world database.
    Yu M; Zhou L; Cao M; Ji C; Zheng Y
    Front Immunol; 2024; 15():1397692. PubMed ID: 39234238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.